The oncogenic fusion protein MOZ-TIF2 is one of several fusion products resulting from reciprocal chromosomal rearrangements in the MOZ/MYST3/KAT6A gene in acute myeloid leukemia. 1 Previous studies have shown that MOZ-TIF2 transforms haematopoietic progenitors 2, 3 and induces acute myeloid leukemia in a murine bone marrow transplant model. 2, 4 MOZ-TIF2 induces widespread changes in histone acetylation, 3, 5 subverting the development of haematopoietic progenitors towards leukaemia. One mechanism critical to the leukaemogenic action of MOZ-TIF2 is its association with the lysine acetyltransferases CBP and p300. 3 This interaction requires a C-terminal activation domain (AD1) present in TIF2. 6, 7 The AD1 sequence forms an amphipathic a-helix that is conserved in proteins such as Ets2, E1A, p160s and IRFs, 6 and which docks with the SID (SRC1 interaction domain) of CBP/p300 to form a stable fourhelix bundle. 7 Mutations in the AD1 a-helix render MOZ-TIF2 incapable of transforming haematopoietic cells and unable to induce leukaemia in a mouse model, 2, 3 indicating that recruitment of CBP/p300 is essential for cell transformation. A consequence of this interaction is the strong depletion of intracellular levels of CBP and p300 via a proteasome-independent mechanism, accompanied by a loss of transcription at p53 and nuclear receptor target genes, including the RARb2 gene. 3, 5 However, the mechanism by which MOZ-TIF2 promotes depletion of cellular CBP/p300 is unknown.
As MOZ-TIF2 did not alter the levels of CBP mRNA as determined by qPCR experiments (data not shown), we investigated whether proteasome or specific protease activities might contribute to the downregulation of CBP/p300. Precedence for this was provided by a study showing that in neuronal cells, CBP is targeted for degradation by calpains and caspases at the onset of apoptosis. 8 In this study, we report that a specific inhibitor of calpains and cathepsins (N-acetyl-leucyl leucyl-methioninal; ALLM or CPI-2) can block MOZ-TIF2-mediated destruction of CBP/p300 and rescue its repressive effects on gene expression. Expression of MOZ-TIF2 in different cell lines results in depletion of CBP from PML bodies and a strong reduction in overall cellular levels of CBP protein. 3, 5 Failure to detect changes in the levels of CBP transcripts indicated that this was likely to be a posttranscriptional effect (data not shown). To explore the underlying mechanism, a stable cell line (U2Os-TRex) carrying an inducible MOZ-TIF2 expression vector 5 was cultured in the presence or absence of doxycycline and treated with a range of small molecule inhibitors of protease or proteasome activities. Western blot analysis on whole cell extracts revealed that, consistent with previous results, cells induced to express YFP-MOZ-TIF2 ( Figure 1a ; Lane 2), (but not YFP or YFP-MOZ-TIF2 DAD1 3 ), showed a strong depletion of CBP and p300 proteins (top and middle panels), in contrast to control proteins such as a-tubulin or b-actin (lower panel). Treatment of cells with the proteasome inhibitors lactacystin (10 mM), MG132 (10 mM) or vehicle for 8 h failed to rescue CBP/p300 levels in YFP-MOZ-TIF2 expressing cells, and did not affect CBP levels in YFP-expressing cells under similar conditions ( Figure 1a , lanes 3,4 and data not shown). These results indicate that the observed reduction in cellular CBP is unlikely to involve proteasomal degradation. Similarly, treatment of cells with a caspase 6 inhibitor (10 mM z-VEID-fmk), which has been reported to inhibit CBP degradation in neuronal cells 8 did not alter the reduced levels of CBP protein observed after YFP-MOZ-TIF2 induction (data not shown). However, pre-treatment of cells with calpain inhibitor 2 (CPI-2; 2 mM) for 8 h before harvesting completely restored CBP and p300 to the levels observed in the controls (Figure 1a , lane 5), whereas vehicle had no significant effect (Figure 1a, lane2) . In contrast, expression of b-actin and a-tubulin proteins, which are not affected by MOZ-TIF2, was also unaffected by CPI-2 treatment (Figure 1a lower panel) . Indeed, CPI-2 did not alter the levels of CBP in mock-transfected HEK293 controls (Figure 1b) indicating that the rescue effect is dependent on MOZ-TIF2. These results implicate the protease targets of CPI-2 (such as calpains I and II and cathepsins) in the degradation of CBP/p300 induced by MOZ-TIF2.
CBP and other proteins associated with leukaemias are often found to localize to PML or nuclear bodies. Cells expressing MOZ-TIF2 display a loss of CBP staining in nuclear bodies. 3 We therefore assessed whether CPI-2 could restore the accumulation of CBP in nuclear bodies. The adherent cell line HEK293 was chosen for this experiment as it gives high quality images of CBP-stained PML bodies, and also we have previously shown that the effects of MOZ-TIF2 on gene expression and CBP/p300 levels are maintained in this background.
3 HEK293 cells were transfected with YFP-MOZ-TIF2 expression vector. After 24 h to allow for expression, cells were treated with CPI-2 (2 mM) or vehicle for 8 h. The cells were then stained by immunocytochemistry using a-CBP antibodies. As shown in Figure 1c , in contrast to non-transfected cells, cells expressing YFP-MOZ-TIF2 and treated with vehicle showed a reduced overall level of CBP staining and in many cases a complete loss of CBP from PML bodies. However, cells pre-treated with CPI-2 showed close to normal levels of CBP, and many cells showed CBP to be present in nuclear bodies, irrespective of the presence of YFP-MOZ-TIF2 (Figure 1c) . To quantify this effect, we repeated the HEK293 transfections using either YFP or YFP-MOZ-TIF2 vectors. After 8 h of treatment with vehicle or CPI-2 (2 mM), YFP þ cells were collected by cell sorting, and scored for the presence of CBP in nuclear bodies (n ¼ 85 minimum). As shown in Figure 1d , 495% of control cells (for example, non-transfected or expressing YFP only) scored positive for the detection of endogenous CBP in nuclear bodies, whereas only 16% of YFP-MOZ-TIF2 cells displayed any CBP staining in nuclear speckles. However, pre-treatment of YFP-MOZ-TIF2-expressing cells with CPI-2, but not vehicle induced a strong increase in the numbers of cells scoring positive for the detection of CBP in nuclear bodies (61%; Figure 1d ). In contrast, CPI-2 treatment had no significant effect on CBP staining to nuclear bodies in controls, that is, in the absence of MOZ-TIF2 (Figure 1c and data not shown) .
We have shown previously that MOZ-TIF2 disrupts liganddependent activation of endogenous or reporter genes by retinoic acid receptors, PPARs and ER.
3,5 Thus, we assessed the effect of CPI-2 on all trans-retinoic acid activation of a RARb2-Luc reporter activated by endogenous RARs and RXRs in COS-1 and U937 cells, in the presence or absence of MOZ-TIF2 ( Figure 2) . As observed previously, all trans-retinoic aciddependent activation by endogenous RAR/RXR (Figures 2a  and b) or GAL-RARa (data not shown) was inhibited by expression of MOZ-TIF2. However, treatment of the cells with CPI-2, but not vehicle, resulted in a substantial rescue of reporter activities in both cell types (Figures 2a and b) . In contrast, no rescue was observed when U937 cells expressing MOZ-TIF2 were treated with proteasome inhibitors such as MG132 (Figure 2a) . Similar results were obtained using a reporter driven 6 MOZ-TIF2 expression was induced by addition of doxycycline (2 mg/ml) to the culture medium.
by GAL4-RARa cells in COS-1 cells (data not shown). Thus the rescue of CBP expression by CPI-2 correlates with a restoration of RAR-dependent transcription, consistent with the hypothesis that depletion of CBP and p300 is at least partly responsible for the observed repression of transcription by RARs and potentially other activators, including p53.
In summary, the functions of CBP and p300, which are important for normal haematopoiesis, are subverted in cells expressing MOZ-TIF2. Our results indicate that the cell permeant calpain/cathepsin inhibitor CPI-2 can block this effect of MOZ-TIF2, restoring CBP expression to normal levels and rescuing MOZ-TIF2-mediated gene repression, for example, at the RARb2 gene promoter. Our results also indicate a role for calpain/cathepsin proteases in the oncogenic action of MOZ-TIF2, and suggest that inhibitors of these enzymes might have therapeutic value in some forms of acute myeloid leukaemia. Cell transfections, reporter assays, western blots and immunocytochemistry were performed essentially as described previously. 3, 6 YFP-positive cells were sorted using a BD FacsAria cell sorter. Inhibitors or vehicle were added to cell cultures 8 h before sorting, fixation or harvesting for the above assays. YFP-HA-MOZ-TIF2, GAL4-RARa, TIF2 and YFP expression vectors have been described previously.
